BrightGene Bio Gross Profit vs. Price To Sales
| 688166 Stock | 29.55 0.68 2.36% |
For BrightGene Bio profitability analysis, we use financial ratios and fundamental drivers that measure the ability of BrightGene Bio to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well BrightGene Bio Medical utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between BrightGene Bio's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of BrightGene Bio Medical over time as well as its relative position and ranking within its peers.
BrightGene |
BrightGene Bio Medical Price To Sales vs. Gross Profit Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining BrightGene Bio's current stock value. Our valuation model uses many indicators to compare BrightGene Bio value to that of its competitors to determine the firm's financial worth. BrightGene Bio Medical is number one stock in gross profit category among its peers. It also is number one stock in price to sales category among its peers . The ratio of Gross Profit to Price To Sales for BrightGene Bio Medical is about 66,777,406 . Comparative valuation analysis is a catch-all model that can be used if you cannot value BrightGene Bio by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for BrightGene Bio's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.BrightGene Price To Sales vs. Gross Profit
Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
BrightGene Bio |
| = | 670.14 M |
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
BrightGene Bio |
| = | 10.04 X |
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
BrightGene Price To Sales Comparison
BrightGene Bio is currently under evaluation in price to sales category among its peers.
BrightGene Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on BrightGene Bio. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of BrightGene Bio position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the BrightGene Bio's important profitability drivers and their relationship over time.
Use BrightGene Bio in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BrightGene Bio position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BrightGene Bio will appreciate offsetting losses from the drop in the long position's value.BrightGene Bio Pair Trading
BrightGene Bio Medical Pair Trading Analysis
The ability to find closely correlated positions to BrightGene Bio could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BrightGene Bio when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BrightGene Bio - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BrightGene Bio Medical to buy it.
The correlation of BrightGene Bio is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BrightGene Bio moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BrightGene Bio Medical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BrightGene Bio can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your BrightGene Bio position
In addition to having BrightGene Bio in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Corporate ETFs Thematic Idea Now
Corporate ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Corporate ETFs theme has 220 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Corporate ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in BrightGene Stock
To fully project BrightGene Bio's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of BrightGene Bio Medical at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include BrightGene Bio's income statement, its balance sheet, and the statement of cash flows.